DAYLI Partners

ALDAVER provides incredibly realistic personalized surgical training models using innovative biopolymer materials that closely resemble human tissues and 3D printing technology.

Medipixel, Inc., founded in 2017 and based in Seoul, South Korea, specializes in developing artificial intelligence-based diagnostic software and semi-autonomous surgical tools for lung cancer and cardiac disease interventions. The company employs a team of experts in computer vision, deep learning, and reinforcement learning, collaborating with leading healthcare institutions to enhance diagnostic and surgical processes. Medipixel offers several innovative solutions, including an AI-based diagnosis tool that assists doctors in identifying lesions during coronary angiography, a guide and planning solution that visualizes hidden coronary artery segments to facilitate guidewire manipulation, and an automated navigation engine that optimizes robotic control for surgical procedures. By integrating advanced AI technologies, Medipixel aims to improve the quality of medical care and patient outcomes in the field of surgery.

Cellemedy is a biotechnology company focused on developing advanced therapeutic proteins as alternatives to conventional antibody treatments. Utilizing a proprietary platform, Cellemedy enhances antigen-binding capabilities, allowing for broader applicability in various medical conditions. The company is dedicated to advancing human health by creating innovative biopharmaceuticals, particularly in the field of cancer immunotherapy. Through its research and development efforts, Cellemedy aims to provide effective cancer cell-related therapeutics and immuno-oncology drugs, helping healthcare professionals improve outcomes for patients battling cancer.

CURAUM Inc. specializes in the development and sale of oral care and sleep-related health care products in South Korea. Founded in 2017 and headquartered in Yuseong, with additional offices in Seoul, Incheon, and Newport Beach, California, the company offers innovative devices designed to improve oral hygiene and manage sleep disorders. Its product lineup includes the Clium Cleaner, which sterilizes and stores dental devices, the Clium S-Guard, an omnidirectional device aimed at treating obstructive sleep apnea and snoring, and the Clium System, a home health care solution that personalizes management of chronic sleep issues. CURAUM also focuses on collecting and analyzing consumer health data to monitor hygiene status and predict symptoms of potential diseases, thereby promoting preventive health habits.

Arum Therapeutics is a pharmaceutical company focused on discovering and developing innovative therapeutics for cancer and oncology-related diseases. The firm is engaged in creating novel anticancer agents designed to address drug resistance, utilizing a platform centered on synthetic lethality targets linked to DNA damage response mechanisms. This approach aims to provide effective treatment options for patients and address unmet medical needs in existing therapies for cancer and respiratory diseases.

Illimis Therapeutics is a biotechnology company focused on developing innovative treatments for neurodegenerative diseases, particularly Alzheimer's disease. The company utilizes a chimeric fusion protein platform to create novel therapeutic options aimed at addressing the unmet medical needs in the treatment of degenerative brain conditions. By leveraging their specialized fusion protein technology, Illimis Therapeutics aims to provide new modalities for patients, enhancing the healthcare industry's ability to combat these challenging diseases.

Generate great Experiance is an IT company that develops IoT equipment for medical platform.

Protium Science is a biopharmaceutical company focused on drug research and development, offering analytical and quality assurance services. The company specializes in the development of drug substances and finished drugs, covering all aspects of chemistry, manufacturing, and controls (CMC). By developing production cell lines and custom medicines, Protium Science aims to enhance patient access to tailored therapeutic solutions.

Gencellmed is focused on developing innovative treatments for cancer using oncolytic viruses, specifically a next-generation immune-enhancing anti-cancer herpes virus known as oHSV-1. The company aims to address unmet clinical needs in cancer therapy by creating drugs that not only stimulate the infectious properties of cancer cells but also enhance the body's immune response to combat the disease effectively. By leveraging this dual-action approach, Gencellmed seeks to provide medical professionals with advanced therapeutic options to improve patient outcomes in cancer treatment.

K-Cell is a biotechnology company that offers cell storage services.

Nuvilab specializes in digital solutions for the food industry, focusing on environmental sustainability and enhancing personal well-being. The company offers an AI-powered food scanner that can instantly identify food types and volumes, facilitating accurate food analysis. By harnessing big data, Nuvilab integrates various food-related information, such as details about leftovers, user preferences, and nutritional benefits. This comprehensive approach allows the company to provide personalized nutritional reports and tailored guidelines, promoting healthier dietary habits among users.

Hmcnetworks leads service innovation, resolving the imbalance of information in the medical industry by using big data.

MxT Biotech is a biotechnology company focused on developing innovative microfluidic platforms for cell engineering and immunotherapies. The company specializes in microfluid-based intracellular material delivery, offering gene-editing services and automated process equipment. Its cell therapy products include non-viral-based intracellular mass transfer platforms, which facilitate the delivery of genes and nucleic acids into cells. By generating flow in microtubules, MxT Biotech's technology creates temporary gaps in cell and nuclear membranes, allowing for efficient material transfer. This approach aims to enhance therapeutic outcomes in various applications, particularly in the fields of cell therapy and immunotherapy.

Cellaputics Bio is a biotechnology company that develops cell therapy for treating degenerative and intractable diseases.

Y-Biologics Inc. is a biotechnology company based in Daejeon, South Korea, specializing in the discovery and development of novel antibody therapeutics, particularly in the field of immuno-oncology. Established in 2007, the company has developed a unique bispecific antibody platform technology known as AliCE, which retains the structure of the parental antibody to ensure high binding affinity to cancer antigens. Additionally, Y-Biologics has created the Y-max ABL library, which comprises a diverse range of antibodies. The company also offers contract research services, further contributing to its position in the antibody drug market. Through its innovative technologies and research efforts, Y-Biologics aims to advance its portfolio of antibody drugs and strengthen its role in the global immuno-chemotherapeutic landscape.

DeepCardio is a company focused on developing artificial intelligence technology for the accurate diagnosis of heart movements. It specializes in systems designed to diagnose paroxysmal atrial fibrillation, employing advanced deep learning techniques. This innovative approach allows healthcare professionals to predict arrhythmias in patients, even during periods when they are not experiencing seizures, thus enhancing the capabilities of cardiac assessments and improving patient outcomes.

Seawith is a biotechnology startup focused on producing cell-cultured steak derived from seaweed. The company has developed Yo.od, a low-iodine seaweed designed for consumers who have low iodine resistance and high iodine sensitivity. Seawith utilizes its own culture media made from microalgae, which not only enhances the nutritional profile but is also more cost-effective due to the plentiful availability of microalgae. By creating clean meat in a laboratory setting, Seawith aims to eliminate the need for raising and slaughtering livestock, delivering a product that mimics traditional meat in taste and texture while being both delicious and affordable.

iN Therapeutics is a biotechnology company focused on developing innovative drug therapies for patients with incurable neurological diseases. The company is engaged in the creation of treatments targeting various conditions, including non-narcotic analgesics for Nav1.7, hearing loss, and other brain-related disorders. By advancing its drug development pipeline, iN Therapeutics aims to provide effective solutions for central nervous system diseases, ultimately enhancing the quality of life for affected individuals.

Space F is an application industry platform business company that researches and develops cell farming technology.

Ubix Therapeutics, Inc. is a research and development company based in Seoul, South Korea, focused on creating anti-cancer drugs through its innovative proteolysis targeting chimera platform technology. This approach employs inhibitor technology to degrade specific target proteins within cells, aiming to enhance therapeutic efficacy for various cancers. By binding to proteins associated with targeted diseases, Ubix Therapeutics seeks to provide effective and life-saving treatments for patients, thereby supporting medical professionals in their efforts to combat cancer.

Lynk Solutec is a laboratory-based company focused on the development of biomedical devices. It specializes in innovative solutions such as a nano-oil film coating that prevents the adhesion of blood, viruses, and bacteria. The company aims to enhance patient treatment through the creation of medical devices that address specific challenges faced in healthcare. Among its products is an anti-fog and anti-blood endoscope cap designed to maintain a clear field of view during procedures. Lynk Solutec's approach is rooted in research and development that responds to the needs and inconveniences encountered in the medical field, offering healthcare professionals effective new tools for enhanced patient care.

LaSemilla is an ag-tech company focused on addressing the food crisis exacerbated by global climate change. It provides a sustainable food production platform and develops crops that are engineered to be more resilient to climate-related challenges. By leveraging advanced biotechnology, LaSemilla aims to enhance food security for businesses and communities, ensuring a reliable food supply in the face of environmental adversity.

GI CELL is a biotechnology company focused on the development of immune cell-based therapeutics aimed at treating complex diseases. Utilizing innovative platform technology, the company specializes in screening and optimizing ancillary proteins that enhance target immune cells for the treatment of conditions such as cancer and inflammatory disorders. Additionally, GI CELL is engaged in the creation of multi-valent sub-unit vaccines for COVID-19, leveraging its expertise in ancillary protein engineering and a deep understanding of immunology. This approach enables medical practitioners to provide effective treatments to patients.

Anterogen is a bio-venture company specializing in research and development of cell therapy products and orphan drugs using adult stem cells.

CasCure Therapeutics specializes in developing personalized chemotherapy solutions aimed at treating cancer. The company leverages artificial intelligence and deep learning technologies to enhance its product offerings, which include Platform C for precision cancer medicines and Platform H for anti-cancer drugs. By utilizing innovative approaches like CRISPR technology, CasCure Therapeutics provides medical professionals with advanced tools designed to improve treatment outcomes and personalize patient care in the fight against cancer.

Tcino Bioscience develops molecule anti-cancer drugs for cancer patients.

Mthera Pharma is a biopharmaceutical research and development company focused on creating innovative treatments through precision medicine. The company is developing a pre-clinical drug that aims to expedite the translation of scientific advancements into effective therapies. Its lead compounds are designed to address multi-target diseases, equipping healthcare providers with the tools to combat conditions such as Parkinson's disease and dementia. Mthera Pharma's work emphasizes the potential of modern science to transform patient care and improve health outcomes.

Pantillogos is a biotech developing next-generation immuno-oncology drugs using immunology, rental and transfer of licenses.

GenEdit Inc., founded in 2016 and based in Berkeley, California, focuses on advancing gene therapy through its innovative genome editing tools, particularly the CRISPR/Cas9 system. The company aims to address the challenges associated with gene therapy delivery by utilizing its proprietary NanoGalaxy™ platform, which systematically screens a library of nanoparticles to enhance the safety and efficiency of delivering genetic material to target tissues. GenEdit's technology is designed to facilitate therapeutic gene editing, offering a solution that is easier, faster, and more accurate than traditional methods. This positions GenEdit to potentially enable the treatment of previously incurable genetic diseases, significantly contributing to the future of non-viral, gene editing-based therapeutics.

Tomocube Inc. specializes in the design and manufacture of 3D optical microscopes, particularly the HT-1 and HT-2 models, which offer holotomographic imaging and 3D fluorescence capabilities. Founded in 2015 and headquartered in Daejeon, South Korea, the company aims to enhance biological and medical research through innovative optical solutions. Unlike traditional optical microscopes that provide only 2D views, Tomocube's products enable researchers to obtain real-time, dynamic 3D images of living cells without the need for extensive sample preparation. This technology is particularly beneficial for studying various biological samples, including red blood cells, sperm cells, CAR-T cells, and more. By utilizing deep learning-based image recognition, Tomocube's microscopes allow for a better understanding of cellular dynamics, ultimately aiding in the diagnosis and treatment of human diseases.

Space F is an application industry platform business company that researches and develops cell farming technology.

Seawith is a biotechnology startup focused on producing cell-cultured steak derived from seaweed. The company has developed Yo.od, a low-iodine seaweed designed for consumers who have low iodine resistance and high iodine sensitivity. Seawith utilizes its own culture media made from microalgae, which not only enhances the nutritional profile but is also more cost-effective due to the plentiful availability of microalgae. By creating clean meat in a laboratory setting, Seawith aims to eliminate the need for raising and slaughtering livestock, delivering a product that mimics traditional meat in taste and texture while being both delicious and affordable.

Cellaputics Bio is a biotechnology company that develops cell therapy for treating degenerative and intractable diseases.

GI Innovation is a South Korean bio-venture company dedicated to the research and development of innovative biologics aimed at treating immuno-oncology and inflammation/immunology diseases. The company employs its proprietary GI-SMART platform technology, which optimizes the development of multi-targeting fusion protein therapeutics, ensuring high quality and productivity. Through its structured translational research approach, GI Innovation focuses on creating new protein-based drugs, particularly in the fields of immuno-oncology and allergy-related conditions, with the goal of improving patient outcomes worldwide.

Newracle Genetics is a bio venture company that develops gene therapy products for neurological diseases.

iN Therapeutics is a biotechnology company focused on developing innovative drug therapies for patients with incurable neurological diseases. The company is engaged in the creation of treatments targeting various conditions, including non-narcotic analgesics for Nav1.7, hearing loss, and other brain-related disorders. By advancing its drug development pipeline, iN Therapeutics aims to provide effective solutions for central nervous system diseases, ultimately enhancing the quality of life for affected individuals.

PharmCADD specializes in creating advanced drug development platforms that leverage artificial intelligence, molecular dynamics simulations, and quantum calculations to enhance the drug discovery process. Its flagship product, Pharmulator, is a comprehensive drug discovery platform that integrates five key modules: protein and RNA 3D structure prediction, drug generation, virtual screening, quantum calculation, and toxicity prediction. This platform aims to produce drug candidates with increased efficacy and safety. Additionally, PharmCADD offers PharmVAC, a vaccine development platform designed to assist users in designing, analyzing, and visualizing RNA sequences for potential vaccine candidates. By addressing the complexities of drug discovery, PharmCADD seeks to streamline and expedite the development of new therapeutics and vaccines.

Mthera Pharma is a biopharmaceutical research and development company focused on creating innovative treatments through precision medicine. The company is developing a pre-clinical drug that aims to expedite the translation of scientific advancements into effective therapies. Its lead compounds are designed to address multi-target diseases, equipping healthcare providers with the tools to combat conditions such as Parkinson's disease and dementia. Mthera Pharma's work emphasizes the potential of modern science to transform patient care and improve health outcomes.

Master Meditech Inc., established in 2019 and located in Seoul, South Korea, focuses on the development of new pharmaceuticals through the identification of protein structures and the application of medicinal chemistry. The company aims to innovate drug discovery by leveraging advanced scientific techniques to create effective therapeutic solutions.

Space F is an application industry platform business company that researches and develops cell farming technology.

Novelty Nobility Inc. is a private biotech company. They are currently focused on the research of novel angiogenesis targets and develop antibody-based therapeutics in ophthalmology and oncology, where angiogenesis plays a key pathogenic role. In ophthalmology, Novelty Nobility first discovered a novel angiogenesis target, Stem Cell Factor(SCF) and c-KIT, which was initially known for its engagement with proliferation and survival of primitive hematopoietic stem cells for a couple of past decades. We believe that anti-SCF/c-KIT could effectively address the unmet medical needs, mostly caused by inherent limitations of anti-VEGFs, in terms of treatment efficacy and long-term safety. Our target discovery is widely and strongly patent-protected in US/KOR and the lead pipeline, NN2101(a full-human monoclonal antibody), is currently under preclinical development.

Idience is a drug development company focused on creating and commercializing innovative medicines to transform cancer treatment. It specializes in the development of oncology drugs that act as potent inhibitors, preventing the repair of DNA single-strand breaks and promoting their conversion to double-stranded breaks, which leads to synthetic lethality in cancer cells. This approach enables targeted treatment of multiple solid tumors, both as monotherapy and in combination with other anti-cancer agents. Additionally, Idience employs advanced artificial intelligence to automatically detect and classify various disorders across multiple imaging modalities, enhancing the ability to analyze medical images and generate structured reports.

Primoris Therapeutics is a medical research and development center.

Elgen Therapeutics develops an anti-cancer therapy platform. The company's platform creates drugs based on a new epigenetic target and the discovery of a new E3 ligase ligand, allowing medical professionals to find treatment for cancer.

Vaxcell Bio Therapeutics is a biotechnology company focused on developing innovative therapies for cancer treatment. The firm specializes in both cell-based and protein-based immunotherapeutics, aiming to create effective anti-cancer drugs and other related medicines. Through its research and development efforts, Vaxcell Bio is committed to advancing treatment options that harness the body’s immune system to fight cancer.

CURAUM Inc. specializes in the development and sale of oral care and sleep-related health care products in South Korea. Founded in 2017 and headquartered in Yuseong, with additional offices in Seoul, Incheon, and Newport Beach, California, the company offers innovative devices designed to improve oral hygiene and manage sleep disorders. Its product lineup includes the Clium Cleaner, which sterilizes and stores dental devices, the Clium S-Guard, an omnidirectional device aimed at treating obstructive sleep apnea and snoring, and the Clium System, a home health care solution that personalizes management of chronic sleep issues. CURAUM also focuses on collecting and analyzing consumer health data to monitor hygiene status and predict symptoms of potential diseases, thereby promoting preventive health habits.

JD Bioscience is a drug development company focused on addressing metabolic disorders that currently lack effective treatments. The company specializes in creating small-molecule therapeutics designed to inhibit biogenesis in peripheral white adipose tissues through a novel mechanism. This innovative approach aims to provide healthcare providers with new options to treat obesity and other related metabolic diseases, thereby contributing to advancements in medical research solutions for these hard-to-cure conditions.

RevoSkectch is a molecular diagnostics company focused on developing digital PCR platform with unique spin partitioning technology. revoskectch is to provide the simplest and affordable digital PCR solutions to life science industry.

MirimGENE is a biotechnology company focused on developing innovative drugs for the treatment of challenging infections and immune disorders. The company aims to create personalized precision medicine by targeting a novel endogenous immune activation factor network. This approach seeks to address infectious diseases that currently lack effective treatments and have high mortality rates, as well as immune conditions resistant to existing therapies. By offering new solutions for patients who have limited options, MirimGENE strives to enhance treatment outcomes in the medical field.

Paprika Care is an online mobile application designed to assist health-conscious individuals in managing their medication. The application allows patients to track their medication intake, set reminders, and monitor their progress. It also provides educational resources about medications, enabling users to stay informed. Additionally, the platform facilitates families and care professionals in remotely overseeing the medication adherence of their loved ones or patients, thereby promoting better health outcomes.

PharmCADD specializes in creating advanced drug development platforms that leverage artificial intelligence, molecular dynamics simulations, and quantum calculations to enhance the drug discovery process. Its flagship product, Pharmulator, is a comprehensive drug discovery platform that integrates five key modules: protein and RNA 3D structure prediction, drug generation, virtual screening, quantum calculation, and toxicity prediction. This platform aims to produce drug candidates with increased efficacy and safety. Additionally, PharmCADD offers PharmVAC, a vaccine development platform designed to assist users in designing, analyzing, and visualizing RNA sequences for potential vaccine candidates. By addressing the complexities of drug discovery, PharmCADD seeks to streamline and expedite the development of new therapeutics and vaccines.

Mthera Pharma is a biopharmaceutical research and development company focused on creating innovative treatments through precision medicine. The company is developing a pre-clinical drug that aims to expedite the translation of scientific advancements into effective therapies. Its lead compounds are designed to address multi-target diseases, equipping healthcare providers with the tools to combat conditions such as Parkinson's disease and dementia. Mthera Pharma's work emphasizes the potential of modern science to transform patient care and improve health outcomes.

AM Sciences is a drug development company focused on creating therapeutic compounds for the treatment of Hepatitis B and liver fibrosis. The company specializes in developing AMS-I series compounds, which act as capsid formation inhibitors. These compounds have demonstrated a significant potential to improve the functional cure rate for chronic Hepatitis B, helping patients alleviate symptoms and prevent the progression of the disease. Through its innovative approach, AM Sciences aims to address critical healthcare needs associated with these conditions.

CSK Inc. is a manufacturer specializing in products for the semiconductor and LCD industries, with a presence in Asia, America, and other international markets. Founded in 1997 and based in Yongin, South Korea, the company provides exhaust management systems, including plasma and wet scrubbers that effectively purify harmful gases produced during semiconductor manufacturing. Additionally, CSK offers precursor delivery systems aimed at waste gas abatement. As of August 2016, CSK operates as a subsidiary of Atlas Copco AB, serving key sectors such as semiconductor, display, solar, and LED markets in South Korea.

Huons Global Co is a holding and pharmaceutical company dedicated to providing medical solutions for human health. Established in 1965, the company has a long history of manufacturing high-quality finished products, including Korea's first local anesthetics and plastic ampoule injections. Huons Global operates through three primary divisions: pharmaceuticals, medical devices, and cosmetics. The pharmaceutical division focuses on the production of ethical drugs, while the medical devices division develops equipment for the safe preparation of platelet-poor plasma and platelet concentrate from blood samples. Additionally, the company offers a range of cosmetic products, including cleansers, creams, and sunscreens. With a commitment to stringent quality control and ongoing research and development, Huons Global exports its pharmaceutical products to approximately 30 countries across North and South America, Europe, Japan, Asia, and Africa.

Sugentech Incorporated is an in-vitro diagnostic company based in Daejeon, South Korea, specializing in personal point-of-care testing products and personalized diagnosis solutions. Founded in 2011, the company focuses on developing innovative healthcare technologies by integrating biotechnology, information technology, and nanotechnology. Sugentech's product offerings include laboratory tests such as immunoblot processors and molecular diagnostics systems, as well as self-diagnostic home testing kits. Their portfolio features tests for various analytes, including C-reactive protein, procalcitonin, and troponin I, along with personal care tests like digital ovulation and pregnancy tests. Formerly known as Accugen Healthcare, Sugentech changed its name in 2013 to reflect its commitment to pioneering advancements in health diagnostics.

Medipixel, Inc., founded in 2017 and based in Seoul, South Korea, specializes in developing artificial intelligence-based diagnostic software and semi-autonomous surgical tools for lung cancer and cardiac disease interventions. The company employs a team of experts in computer vision, deep learning, and reinforcement learning, collaborating with leading healthcare institutions to enhance diagnostic and surgical processes. Medipixel offers several innovative solutions, including an AI-based diagnosis tool that assists doctors in identifying lesions during coronary angiography, a guide and planning solution that visualizes hidden coronary artery segments to facilitate guidewire manipulation, and an automated navigation engine that optimizes robotic control for surgical procedures. By integrating advanced AI technologies, Medipixel aims to improve the quality of medical care and patient outcomes in the field of surgery.

Curiox Biosystems Pte. Ltd. is a bioinstrumentation company based in Singapore, specializing in the development and commercialization of innovative assay platforms. Founded in 2007 and spun out of the Agency for Science, Technology, and Research (A*STAR), Curiox focuses on enhancing life sciences, drug discovery, and diagnostics through the miniaturization and automation of bioassays. The company offers a range of products, including DropArray microplates for miniaturized cell and Luminex assays, as well as various washing stations designed for both automatic and manual loading. Their technology, including the Laminar Wash systems, improves the efficiency and reproducibility of cell processing and analysis. Curiox's product offerings also include plates, fluids, and service contracts, catering to applications such as bead-based immunoassays, suspension cell assays, high content assays, and induced pluripotent stem cells.

Alodokter is a digital health platform based in Indonesia that offers a comprehensive solution for patients seeking healthcare services. It provides telemedicine services, allowing users to consult with qualified doctors remotely. The platform also features credible health information, supportive communities, and extensive reference materials on health topics, empowering users to make informed decisions regarding their health. Additionally, Alodokter facilitates the booking of doctor appointments and offers guidance on illnesses, treatments, and healthy living. By integrating these services, Alodokter aims to enhance the healthcare experience for Indonesian patients and improve access to reliable health resources.

MDimune Inc. is a therapeutics company based in Seoul, South Korea, established in 2015. It specializes in developing innovative drug delivery systems, particularly utilizing vesicles derived from immune and stem cells. The company focuses on creating targeted delivery methods to enhance the efficacy of treatments for conditions such as cancer, osteoarthritis, chronic obstructive pulmonary disease, and neurodegenerative diseases. MDimune's BioDrone platform enables the manufacture and supply of these vesicles, allowing biotechnology and pharmaceutical firms to develop novel therapeutics aimed at delivering drugs precisely to target tissues. This approach facilitates the provision of advanced anticancer therapies to patients, aligning with the company's mission to improve treatment outcomes through smart drug delivery solutions.

HUINNO, Inc., founded in 2014 and headquartered in Boston, Massachusetts, develops healthcare devices that monitor vital health data, including blood pressure, heart rate, electrocardiogram (ECG), and blood oxygen saturation levels (SpO2). The company leverages proprietary technologies in wearable devices and artificial intelligence to provide healthcare providers with an effective remote patient monitoring solution aimed at improving the management of chronic cardiac diseases. HUINNO's clinically-tested platform delivers real-time measurements with clinical-grade accuracy and offers an application and cloud-based ecosystem for longitudinal analysis of health trends, medication compliance, and lifestyle habits. This comprehensive approach not only enhances patient care but also aids healthcare professionals in making informed medical decisions while treating conditions such as arrhythmia and hypertension. With additional offices in New York and Seoul, HUINNO is committed to transforming the way clinicians and patients manage chronic health issues.

StemLab is a Korean biotech company that is developing therapeutic solutions to treat diseases and injuries that have no alternative cures. In particular, it develops cells that can regenerate the central nervous system tissues based on its cell reprogramming technology that transforms somatic cells into stem cells. Stemlab’s cell reprogramming technology takes fully differentiated cells and reprograms them into neural stem cells, allowing them to obtain the stem cells necessary to create stem cell therapies. It thus avoids the ethical issues concernng embryonic stem cell research. Also, its reprogrammed neural stem cells have expansion capability comparable to neural stem cells derived from pluripotent stem cells. And since StemLab obtains somatic cells through urine, harvesting is much less invasive than using cells obtained using other invasive means. StemLab's technology is backed up with 18 patents for original technology related to stem cell treatments and has three patents for application technology, with another five pending. Its initial clinical programs will involve patients with spinal cord injury (SCI) and Amyotrophic Lateral Sclerosis (ALS) or (Lou Gehrig's Disease.

Hisense Bio offers treatment for intractable dental diseases. They provide research on original technology for tooth development and dentin regeneration. They developed physiological dentin regeneration technology and periodontal ligament regeneration technology based on basic dental research . They offer treatment of intractable dental diseases such as tooth decay, dental hypersensitivity, tooth decay, dental caries, and periodontal disease.

Cytodx is a bio-venture company focused on developing advanced technology for isolating and culturing target cells found in blood. The company specializes in liquid biopsy technology, which allows for the diagnosis of various cancer types by analyzing genetic material, such as DNA from cancer cells, in body fluids like blood and urine. This innovative approach enables healthcare professionals to detect cancer at an early stage through non-invasive blood tests. In addition to its diagnostic capabilities, Cytodx is working on an automated platform that enhances the precision of cancer diagnosis and treatment, as well as life cycle monitoring technology aimed at improving cancer management.

Tomocube Inc. specializes in the design and manufacture of 3D optical microscopes, particularly the HT-1 and HT-2 models, which offer holotomographic imaging and 3D fluorescence capabilities. Founded in 2015 and headquartered in Daejeon, South Korea, the company aims to enhance biological and medical research through innovative optical solutions. Unlike traditional optical microscopes that provide only 2D views, Tomocube's products enable researchers to obtain real-time, dynamic 3D images of living cells without the need for extensive sample preparation. This technology is particularly beneficial for studying various biological samples, including red blood cells, sperm cells, CAR-T cells, and more. By utilizing deep learning-based image recognition, Tomocube's microscopes allow for a better understanding of cellular dynamics, ultimately aiding in the diagnosis and treatment of human diseases.

Genomictree, Inc. is a molecular diagnostics company focused on developing epigenomic biomarker-based technologies. The company aims to address unmet needs in the healthcare market by providing innovative diagnostic solutions. Through its research and development efforts, Genomictree seeks to enhance patient care and improve health outcomes by leveraging advanced molecular diagnostic tools.

Noul provides innovative solutions aimed at addressing chronic and systemic healthcare challenges. The company focuses on improving medical access through advanced in vitro diagnostics, contributing to the eradication of both infectious and non-infectious diseases that threaten global health. One of its key offerings is the miLab, an all-in-one, fully automated device capable of processing sample preparation and AI diagnostics in a single workflow. This device integrates technologies from computer vision AI, biology, hardware, and software engineering, positioning Noul as a leader in the development of effective diagnostic solutions.

ViGenCell is a medical company focused on immune cell therapy products. The company develops various therapies that aim to improve the quality of life and extend the life expectancy of patients with incurable diseases. Through its innovative approach to treatment, ViGenCell seeks to address significant medical needs in the field of immune-related conditions.

Genoplan is focused on democratizing healthcare by utilizing population genomics and deep learning technologies. The company offers a personal genetic testing product, featuring a DNA testing kit that analyzes saliva samples to provide users with insights about their genetic predispositions. This analysis results in personalized lifestyle recommendations, including advice on diet, exercise, and cosmetics, all presented in easy-to-understand reports. By making genomic information accessible, Genoplan aims to empower individuals to make informed health decisions and contribute to the progress of precision medicine, ultimately helping people take control of their well-being.

SCM Lifescience, founded in 2014, focuses on the research and development of innovative treatment options for challenging diseases, aiming to improve patient outcomes and contribute to public health. The company specializes in proprietary stem cell isolation and production technologies, which form the basis of its products, including medicines and hair care solutions. Based in South Korea, SCM Lifescience is committed to advancing medical science through its development of stem cell products and therapies, providing hope for patients with difficult-to-treat conditions.

Carelabs operates as a digital beauty and healthcare company. We provide medical services that anyone can easily and conveniently access through reliable medical information.

Ensol Biosciences Inc. is a biopharmaceutical company based in Daejeon, South Korea, focused on developing innovative therapies for diseases that currently lack effective treatments, including degenerative disc disease, osteoarthritis, cancer, type 1 diabetes, and Alzheimer's dementia. The company's drug pipeline features several candidates, such as Peniel 2000, which is undergoing Phase II clinical trials for degenerative disc disease, and Engedi 1000, currently in Phase I trials for osteoarthritis. Ensol also develops oncology drugs like Charis 1000 for triple negative breast cancer and Moriah 1000 for Alzheimer’s disease. In addition to its drug development efforts, the company offers contract drug development services and operates the Knowledge-based In Silico Drug Discovery (KISDD 2.0) platform for screening potential drug candidates. Ensol Biosciences was founded in 2001 and rebranded from Ensoltek Co., Ltd. in 2015.

3D MediVision, Inc. specializes in developing and manufacturing 3D visualization and live-casting systems specifically designed for surgical applications. Established in 2011 and based in Seoul, South Korea, the company offers a range of products including 3D/2D cameras, recorders, monitors, and ultrasound systems. Its technology enables surgeons to capture and display surgical procedures in high-definition 3D images, which can be streamed or recorded for educational purposes. Additionally, 3D MediVision provides SURGFLIX, a surgical content sharing platform for professionals, and VeterFlix, tailored for veterinary training. The company's products are distributed through authorized partners in various countries, including India, Spain, Mexico, and China, facilitating enhanced collaboration and knowledge sharing among surgical teams.

Y-Biologics Inc. is a biotechnology company based in Daejeon, South Korea, specializing in the discovery and development of novel antibody therapeutics, particularly in the field of immuno-oncology. Established in 2007, the company has developed a unique bispecific antibody platform technology known as AliCE, which retains the structure of the parental antibody to ensure high binding affinity to cancer antigens. Additionally, Y-Biologics has created the Y-max ABL library, which comprises a diverse range of antibodies. The company also offers contract research services, further contributing to its position in the antibody drug market. Through its innovative technologies and research efforts, Y-Biologics aims to advance its portfolio of antibody drugs and strengthen its role in the global immuno-chemotherapeutic landscape.

WSG is a manufacturer and supplier specializing in precision-engineered flow components designed for ultra-high-purity (UHP) applications. The company develops automated and fully integrated welded tube production systems to serve various sectors, including semiconductors, LCD/OLED displays, microelectronics, biotechnology, life sciences, and pharmaceuticals. By providing vertically integrated manufacturing systems, WSG offers clients efficient and high-precision solutions tailored to their specific needs.

Celemedi is a technology-based drug development company that develops immune anti-cancer drugs.

Cellid is a research and development bioventure company. The company is developing immunotherapeutic vaccines, CeliVax. The CeliVax is a personalized vaccine which uses patient's own cells.

Mediogen is a life science company focused on the research and development of probiotic medicinal products. It specializes in supplying probiotic raw materials for use in functional foods, general food products, and cosmetics. Utilizing patented coating technology, Mediogen aims to enhance the effectiveness of its probiotics, thereby promoting healthier lifestyles for consumers. The company's commitment to innovation in the probiotic sector positions it as a significant player in the life sciences industry.

Live Cell Instrument specializes in the development and manufacturing of advanced imaging systems and microscopes, along with a range of scientific instruments and laboratory consumables. The company's product lineup includes automated imaging systems, microscope incubators, magnetic imaging chambers, heating systems, and LED excitation systems. These offerings are designed to support the bio-industry by providing modern tools for research, enhancing the capabilities of scientists and researchers in their work.

42Maru, Inc. is a South Korean company founded in 2015 that specializes in developing advanced search engine technology for artificial intelligence applications. The company focuses on creating a deep learning-based question-answering (QA) system that accurately interprets user intent to provide unique, correct answers. This technology is applicable across various platforms, including smart speakers, connected cars, and chatbots. 42Maru's core competencies include high accuracy, rapid response times, and a self-expanding knowledge base, distinguishing it from traditional rule-based and inference-based systems. The company aims to penetrate the consumer market through strategic B2B2C alliances, targeting sectors such as home IoT, personal assistants, and smart toys. With a strong team led by a CEO with over 20 years of experience in the search engine industry, 42Maru is positioned for global expansion and multi-language support, capitalizing on the growing demand for AI-driven search solutions.

Tiernes is a dental practice that specializes in digital-based clear orthodontics.

NeuroXT develops software products including NEXT-ATN, NEXT-ALZ-CDx, and NEXT-S.